You are here: Home:  CCU 3 | 2005: Paulo M Hoff, MD: Select publications


Select publications

Cassidy J et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial. Proc ASCO 2004;Abstract 3509.

Giantonio BJ. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO GI Cancer Symposium;Abstract 169a.

Mitchell EP et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO Gastrointestinal Cancer Symposium 2005;Abstract 169a.

 

Table of Contents Top of Page

Home

Editor’s Note:
Is capecitabine the “AC” of
adjuvant therapy for colorectal cancer?
 
Leonard B Saltz, MD
- Select publications
 
Paulo M Hoff, MD
- Select publications
 
Michael J O’Connell, MD
- Select publications
 

Faculty Disclosures

A CME Audio Series
and Activity

Editor's office

 
Terms of Use and General Disclaimer.
Copyright © 2005 Research To Practice. All Rights Reserved.